Côte d'Ivoire vs Luxembourg: Prevalence rate of hypertension in men aged 30-79
Côte d'Ivoire
36.9
in 2019
Luxembourg
36.6
in 2019
Côte d'Ivoire rank
101st
Luxembourg rank
104th
Prevalence rate of hypertension in men aged 30-79 over time
- Côte d'Ivoire
- Luxembourg
How they compare
Côte d'Ivoire currently reports 36.9 against 36.6 in Luxembourg, a difference of 0.3.
The two have swapped places 1 time across 30 shared years of data; in 1990 it was Luxembourg ahead.
Côte d'Ivoire ranks 101st and Luxembourg ranks 104th of 195 countries.
Luxembourg has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Côte d'Ivoire | Luxembourg | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 38.56 | 46.69 | 8.13 | Luxembourg |
| 2000s | 40.19 | 46.05 | 5.86 | Luxembourg |
| 2010s | 38.6 | 40.41 | 1.81 | Luxembourg |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in men aged 30-79, Côte d'Ivoire or Luxembourg?
- Côte d'Ivoire, at 36.9 against 36.6 in Luxembourg as of 2019.
- What is the difference in prevalence rate of hypertension in men aged 30-79 between Côte d'Ivoire and Luxembourg?
- 0.3, with Côte d'Ivoire ahead.
- How many years of comparable data are there for Côte d'Ivoire and Luxembourg?
- 30 years are reported by both, from 1990 to 2019.
- How do Côte d'Ivoire and Luxembourg rank globally for prevalence rate of hypertension in men aged 30-79?
- Côte d'Ivoire ranks 101st and Luxembourg ranks 104th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in men aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of male population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.